“We believe this self-monitoring capabilities of the implant can significantly enhance the treatment and make it significantly better for the patient,” said Bar-Ilan’s Yossi Mandel, who co-authored the paper with Ismail Araci, Baolong Su and Stephen R. Quake of Stanford.
巴伊兰大学的约西o曼德尔表示:“我们认为,这款可植入眼压传感器带来的自我监测能力,可以显著提高青光眼的治疗,并改善患者的处境。”《自然医学》杂志上的这篇论文就是曼德尔与斯坦福大学的伊斯梅尔o阿拉西、苏宝龙(音译)和史蒂芬oRo奎克合作撰写的。
“Today, we think we are not treating them good enough,” he added. “They come once in a while and we take a single point in time of measurement. This probably is not good enough and we know from other studies that there is large variation in the IOP. In the same day, it can vary a lot.”
曼德尔补充道:“现在,我认为我们对青光眼治疗得还不够好。患者偶尔到医院来一趟,然后我们测量到的是他们在某个时间点上的眼压。这可能不够好。我们从其它研究得知,眼压会有很大变化。哪怕在同一天里,眼压也会有很大的变化。”
Glaucoma is a group of eye diseases that in most cases produces increased pressure within the eye and affects more than 65 million people worldwide. When the eye pressure is increased, the optic nerve becomes damaged, resulting in the death of the retinal cells, degeneration of the nerve fibers and eventually permanent loss of vision.
【青光眼患者福音:用手机测眼压】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15